Highlights from EAN 2021 — Day 3
Progress in Mind’s coverage of the 7th Congress of the European Academy of Neurology – Vienna 2021 continues today on Day 3, 21 June. A further full program of inspirational and thought-provoking live scientific, educational, industry, and social events was provided for the virtual attendees. Here are today’s highlights and we hope you enjoy the final day of the congress tomorrow.
Migraine—the future treatment paradigm and improving diagnosis
For those up early enough, an early bird satellite symposium considered the future treatment paradigm for patients with migraine following the introduction of effective and well-tolerated therapies targeting calcitonin-gene related peptide; and how this will alleviate the migraine burden and improve quality of life for patients.
This was then followed by a focused workshop on improving migraine diagnosis in the era of precision medicine; and a satellite symposium on the consequences of migraine, from episodic migraine to medication overuse, highlighting the importance of preventive therapy.
Alzheimer’s and Parkinson’s diseases
An in-depth fascinating state-of-the-art exploration of the neuropathology of dementias and Parkinson’s disease was provided in an EAN/European Confederation of Neuropathological Societies 3-hour educational session.
During this session, presentations were given by pioneers in the field—Professor Dietmar Thal, who focused on amyloid in Alzheimer’s disease and the coexistent multiple pathologies that occur in the brains of elderly people; Professor Gabor G. Kovacs, with a presentation on the tauopathies and the relevant diagnostic implications; Dr Marta Scarioni, who revealed the many faces of TDP-43 protein; and Professor Steve Gentleman, who provided an update on alpha synucleinopathies.
The final session of a 3-day satellite symposium on the Alzheimer’s disease journey provided expert insights into the optimal and future management of patients and their families.
Other presentations included an EAN/Movement Disorder Society’s European Section scientific session on precision medicine in Parkinson’s disease, and an EAN/European Association of Nuclear Medicine educational session on characterizing cognitive impairment in synucleinopathies.
As on previous days, there were plenty of 2-minute e-poster sessions on a wide range of relevant topics.
Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.